MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
nChroma Bio
Organization & Developments: nChroma
Parents
nChroma Bio
Children
* Company’s integrated product engine overcomes limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery.
* nChroma’s near clinical-stage development candidate, CRMA-1001, is a liver-targeted therapy in development as a potential functional cure for chronic hepatitis B and hepatitis D that leverages the power of epigenetics
*Developing transformative treatments using programmable in vivo delivery of tailored and long-lasting genetic medicines designed to overcome the limitations of today’s therapies.
*nChroma Bio is developing in vivo targeted genetic medicine to treat a wide array of diseases
*Offers liver-targeted therapy for chronic hepatitis B and D and leverages epigenetics to enable safe, precise and specific gene regulation
2024: Chroma, Nvelop merge to form nChroma Bio, raising $75M to enter the clinic
Chroma Medicine*
Nvelop Therapeutics
Jumps
Finance & Acquisition: nChroma Bio
Key People: nChroma Bio